Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue - Marketscreener.com
| ANNX Stock | SEK 0.50 0.01 1.96% |
Slightly above 62% of Annexin Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Annexin Pharmaceuticals AB suggests that many traders are alarmed regarding Annexin Pharmaceuticals' prospects. Annexin Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Annexin Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Annexin |
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue Marketscreener.com
Read at news.google.com
 |
Annexin Pharmaceuticals Fundamental Analysis
We analyze Annexin Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annexin Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annexin Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Annexin Pharmaceuticals is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Annexin Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Annexin Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Annexin Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Annexin Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Annexin Pharmaceuticals Related Equities
| BIOA-B | BioArctic | 2.99 | ||||
| BIOVIC-B | Biovica International | 0.43 | ||||
| CANTA | Cantargia | 1.64 | ||||
| ACE | Ascelia Pharma | 3.65 |
Additional Tools for Annexin Stock Analysis
When running Annexin Pharmaceuticals' price analysis, check to measure Annexin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexin Pharmaceuticals is operating at the current time. Most of Annexin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Annexin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Annexin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.